In Depth 5 Sep 2025 Closing treatment gaps in yellow fever: are germ-free egg-based vaccines the answer? Germ-free egg-based vaccines could be the answer to curbing yellow fever outbreaks. September 5, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 1 Aug 2025 Oncolytic virus therapy for cancer: what’s been going on in 2025? This past year has seen various developments in the field of oncolytic virus therapies – in fundraising and in the clinic. August 1, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Apr 2025 Seven biotechs to watch in the hepatitis B space Here we take a look at seven biotechs with clinical drug candidates on a quest to win regulatory approval to treat HBV. April 22, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 15 Jul 2024 Fighting EEHV in elephants: How mRNA vaccines can offer hope against viruses affecting animals Discover how a new mRNA vaccine could help to tackle EEHV in elephants, which is a number one killer of Asian elephant calves. July 15, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2024 CRISPR-Cas13: how does the technology compare to its famous Cas9 cousin? Discover more about CRISPR-Cas13, including how it differs from CRISPR-Cas9 and what the technology can be used for. June 27, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 3 Apr 2024 Hepatitis B: are we edging closer to a cure? Find out whether we are closing in on a cure for hepatitis B – a virus affecting the liver that can cause acute and chronic disease. April 3, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 14 Mar 2024 7 oncolytic virus companies you should know about Find out more about 7 oncolytic virus companies advancing their drug candidates through clinical trials to help cancer patients. March 14, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2023 Swedish researchers look to peptides to destroy viruses A new study from Sweden shows how a type of peptide from a lactic acid bacterium destroys viruses, including coronavirus. The findings have resulted in a Swedish patent, with an international patent pending. “We’re hoping for a quick turnaround to allow this discovery to be utilised in antiviral treatments and as a complement to vaccine,” […] July 7, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 30 Jun 2023 Virus tracking could be key to kidney transplant patients’ drug choices By Dr Gregor Bond More than 15,000 Europeans undergo kidney transplants on average each year, and while medical advances have helped many recipients enjoy healthy lives, the risks of organ rejection and infection remain huge challenges. With each transplant, success depends on using carefully balanced doses of immuno-suppressive drugs to reduce the risk of infection […] June 30, 2023 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 10 May 2023 Delivering on the need for vector innovation in genetic medicine By Tuyen Ong, CEO Ring Therapeutics, CEO-Partner Flagship Pioneering Gene therapy is a life-changing class of medicine that can treat patients with once intractable diseases. While revolutionary, significant limitations remain for the vectors that carry them. Viruses are masters at delivering genetic material to the nucleus of the organisms they infect, and because of this, […] May 10, 2023 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2023 FDA fast track for Memo’s kidney transplant infection treatment Memo Therapeutics AG, a biotech company developing therapeutic antibodies, says the U.S. Food and Drug Administration (FDA) has granted fast track designation to AntiBKV, Memo Therapeutics’ lead antibody therapeutic that targets BK polyomavirus (BKV) infection commonly seen in renal transplant patients. AntiBKV has successfully completed a phase I clinical study and following FDA clearance has […] May 2, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine Ethris GmbH is to collaborate with U.K.-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of betacoronaviruses. The efforts will utilize Ethris’ mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilization platforms. The collaboration is founded on a $42 million award to DIOSynVax by the […] December 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email